Based on its closing price on January 8, the company had reported returns of 9.01% in the last week, -6.19% in the last month, and -15.36% in the last quarter.
The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index jumped to a 14-year high…
Eli Lilly (LLY) plans to release its 4Q17 and 2017 earnings on January 31, 2018. For 4Q17, analysts expect LLY to report earnings per share of $1.07 on revenues of ~$5.9 billion.
Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.
Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).
Incyte’s revenue sources include revenue from Iclusig sales in European markets, Jakafi sales in US markets, and royalties from Jakavi and Olumiant sales.
Eucrisa growth trends On December 14, 2016, Pfizer (PFE) announced that it had secured FDA approval for its mild-to-moderate AD (atopic dermatitis) therapy, Eucrisa (crisaborole) 2% ointment, for patients over two years old. This drug was added to Pfizer’s portfolio through the acquisition of Anacor Pharmaceuticals, which was completed in June 2016 for ~$5.2 billion. […]
In 3Q17, Johnson & Johnson’s (JNJ) Zytiga generated revenues of $669 million, which reflected ~15% growth on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter basis.
Gilead’s other products As discussed earlier, Gilead Sciences’ (GILD) other products include cardiovascular, inflammation, oncology, and respiratory products. The above chart compares Gilead’s revenue from other products over the last few quarters. Between 3Q16 and 3Q17, revenue from other products fell 1% to $559 million from $564 million. Cardiovascular drugs Letairis, Lexiscan, and Ranexa are Gilead’s cardiovascular products. […]
In its 3Q17 earnings conference call, Merck & Co. (MRK) announced its plans to capture long-term overall survival data in its pivotal Keynote-189 study.
In 3Q17, Eli Lilly’s (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.
On November 10, 2015, the FDA approved Exelixis’s (EXEL) Cotellic in combination with Roche Holdings’ (RHHBY) Zelboraf (vemurafenib) as a treatment option.
Zimmer Biomet Holdings’ (ZBH) S.E.T. (Sports, Extremities, and Trauma) segment registered sales of $407 million, contributing 23% to the company’s total revenues.
Wall Street analysts estimate that Pfizer’s top line will rise 1% YoY to ~$13.18 billion in 3Q17. Its EPS (earnings per share) are expected to rise to $0.64.
Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.
Renewed tensions arising out of North Korea’s missile launch on Tuesday had a major impact on volatility. Asian markets have declined more than 1% as risk aversion dominated markets.
Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]
Segment-wise performance Johnson & Johnson (JNJ) reported a revenue increase of ~2.9% between 2Q16 and 2Q17. The company’s business is broken down into three business segments: Pharmaceuticals, Consumer Products, and Medical Devices. At constant exchange rates, the company reported growth across all segments. Segment-wise revenue The pharmaceutical segment, which contributes nearly 45.8% of Johnson & Johnson’s […]
Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.
Johnson & Johnson’s Ppharmaceuticals segment includes products from various franchises: cardiovascular and metabolics, immunology, infectious disease, neuroscience, and oncology.
Keytruda, a prescription medicine classified under Merck’s (MRK) immunooncology franchise, is used to treat non-small cell lung cancer as well as melanoma.
Pfizer’s (PFE) portfolio includes medicines, vaccines, and consumer healthcare products. It segregates its operations into Innovative Health and Essential Health.
Edwards Lifesciences has established itself as a leader in the artificial heart valves market and has produced enormous long-term value over the years.
On September 27, Pfizer completed the acquisition of Medivation. The stock transaction is valued at $81.50 per Medivation share for a total of ~$14 billion.
Medical devices segment Johnson & Johnson’s (JNJ) Medical Devices segment grew ~1.1% to ~$6.2 billion between 3Q15 and 3Q16. This growth included an operational increase of 0.7% and a positive impact of foreign exchange. Cardiovascular care franchise The cardiovascular care franchise’s sales fell 13.9% to $451 million in 3Q16. This fall was due to the […]
As we discussed earlier, Eli Lilly and Co.’s (LLY) 3Q16 segment performance is expected to be positive for both its human pharmaceuticals and animal health segments.
Januvia and Janumet are two blockbuster drugs in Merck & Co.’s diabetes franchise. These drugs are used to lower blood sugar levels in patients with type 2 diabetes.
Pfizer’s businesses Pfizer’s (PFE) portfolio comprises medicine, vaccines, and consumer healthcare products. The company has segregated its operations into two businesses: Innovative Health and Essential Health. Business segments The above chart shows revenues for the last few quarters and revenue estimates for the next two quarters. Pfizer’s Innovative Health segment, which was previously referred to as […]
The acquisition of Cepheid (CPHD) in the strategic sense is a gateway for Danaher (DHR) to breathe life into its limited molecular testing capabilities.
Pfizer’s Innovative Health business reported a growth of 9% in revenues at constant exchange rates to $7.1 billion, as compared to ~$6.6 billion for 2Q15.
Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$898 million, or ~38%, came from Baxter’s Renal Products business.
This year, the healthcare sector seems to be receding, and the utilities sector seems to be in good gear. This is a sign that the early bear phase is over.
In 2015, HCA Holdings’s bad debt expense—represented by the provision for doubtful accounts—totaled $3.9 billion. It rose by ~23.5% YoY (year-over-year).
In 4Q15, Anthem’s medical care ratio, a ratio of medical costs against premium revenues, rose by 2.5% YoY. Its medical care ratio for fiscal 2015 was 83.3%.
Aetna’s Humana acquisition is mainly aimed at increasing the combined companies’ exposure to the high-growth Medicare business. The deal is currently being scrutinized by antitrust regulators.
Thermo Fisher Scientfic (TMO) is expected to witness growth in revenues as well as earnings across all segments of the company in 4Q15 as well as 1Q16.
The Pfizer–Allergan deal could be beneficial to the combined entity in different ways. The combined entity has innovative and established product portfolios.
To extend cost-effective, high-quality medical devices and therapies, Medtronic aims to organize its marketing and sales teams around physician preferences.
The Gardasil franchise is Merck & Co.’s (MRK) leading vaccine franchise. Gardasil is a vaccine that prevents certain strains of HPV (human papillomavirus).
Januvia and Janumet are two blockbuster drugs in Merck & Co.’s diabetes franchise. They’re used to lower the blood sugar level in patients with type-2 diabetes.
